OA Treatment - AM1101
OA Treatment - AM1101
AMPLICORE
Restoring Mobility
Amplicore's Team
Tina Chen, MA, CCRC
Director of Clinical Affairs
Pharmaceutical Project Manager
Pharmaceutical Project Manager
C. James Lin, PhD
Founder
President & Chief Executive Officer
Francis J. Tinney Ph.D., J.D.
Senior Patent Counsel
Tyler Vandivort, PhD
Senior Manager of Regulatory Affairs
James Hamby, PhD
Executive Vice President
Chief Operation Officer
Tina Chen, MA, CCRC
Director of Clinical Affairs
Administrative Coordinator
Amalia Tollas
Felix Chang, JD
General Counsel
VP of Finance & Administration
Stacey Gruber, PhD
Pharmaceutical Project Manager
Advisory Board
Michael Archdeacon, MD
Chair, Amplicore Advisory Board
Dr. Archdeacon is the Peter J. Stern Professor and Chairman of the Department of Orthopaedic Surgery at University of Cincinnati College of Medicine. As a prominent leader in the orthopaedic society, Dr. Archdeacon will help chair the Advisory Board for Amplicore. He will also provide his clinical expertise and guidance to facilitate the translation of the Amplicore technologies to the orthopaedic clinic.
Advisor
Andrew A. Freiberg, MD
Dr. Freiberg is an attending surgeon at Newton Wellesley Hospital in Boston as part of Mass General Brigham, where he specializes in the treatment of osteoarthritis. He is the former Chief Medical Officer of Zimmer Biomet and previously worked for twenty years as Chief of the Hip and Knee Unit at Massachusetts General Hospital. He was also the Interim Department Chair of the Department of Orthopedic Surgery at MGH and a Professor of Orthopedic Surgery at Harvard Medical School. Dr. Freiberg brings to the Board a wealth of experience in primary and revision arthroplasty, arthroscopic treatments, and business management and commercialization of orthopaedic new products.
Vijay Baragi, PhD
Advisor
Dr. Baragi is the Chief Scientific Officer at the Center for Neurologic Studies in Dearborn, Michigan. He is an expert in the development of intra-articular cartilage repair and regeneration strategies for the treatment of osteoarthritis (OA) – a key target of Amplicore’s technologies. He was among the leadership for drug discovery and development in osteoarthritis and inflammation therapeutic areas through his long career at Park-Davis/Pfizer and Alantos Pharmaceuticals (acquired by Amgen in 2007). His wide-ranging experience spans drug discovery, preclinical and clinical development, and regulation, as well as senior executive experience in the pharmaceutical industry. Dr. Baragi brings to the Board expertise and guidance on the crucial pre-clinical and clinical phases.
Joseph Cheng, MD
Advisor
Dr. Cheng is the Frank H. Mayfield Chair of Neurological Surgery at University of Cincinnati College of Medicine. Formerly professor and vice chair of neurosurgery at the Yale School of Medicine, Dr. Cheng is an expert in complex spinal surgery, and is recognized nationally for his neurosurgery outcomes research which has led to improved patient care. Dr. Cheng will provide his insight for the Amplicore’s technologies to assist in spinal disorders and potentially other neurological diseases.
John Kuo, MD, PhD
Advisor
Dr. Kuo is the Inaugural Chair and Professor of Neurosurgery at the University of Texas, Austin, and the Director of the Mulva Clinic for Neurosciences. Dr. Kuo provides his insight for the Amplicore’s technologies to assist in spinal disorders and potentially other neurological diseases.